An Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2586881 in Participants With Pulmonary Arterial Hypertension
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2018
At a glance
- Drugs GSK 2586881 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 10 Aug 2018 Planned number of patients changed from 25 to 24.
- 15 Mar 2018 Planned End Date changed from 17 Oct 2019 to 28 Oct 2019.